NBP

I-Mab

A maker of antibody-based cancer medicines, this biotech develops immuno-oncology therapies including felzartamab, approved in China for multiple myeloma. The company was formed when Dr. Jingwu Zang merged two biotech firms, Third Venture Biopharma and Tasgen Biotech, to create I-Mab. Its name pairs the "I" of immuno with "-mab," the universal scientific suffix for monoclonal antibody drugs. After relocating its base to the United States, the firm rebranded as NovaBridge Biosciences in 2025.

American Depositary Shares

No proxy statement recorded.